...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Urology >Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report.
【24h】

Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report.

机译：经直肠高强度聚焦超声治疗T1b-2n0m0期局限性前列腺癌患者的初步报告。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

OBJECTIVES: To present our preliminary clinical results of transrectal high-intensity focused ultrasound (HIFU) in Stage T1b-2N0M0 prostate cancer. Efforts are being made to provide minimally invasive alternative treatment options with equal efficacy and fewer side effects. HIFU delivers ultrasound energy with rapid thermal necrosis of tissue in the focal region without damaging the surrounding tissue. METHODS: We performed 28 HIFU treatments in 20 patients with biopsy-proven localized prostate cancer using a modified Sonablate-200 HIFU device. All patient characteristics and the clinical outcome of 20 patients followed up more than 6 months (mean 13.5) were analyzed. RESULTS: A complete response was obtained in 100% (20 of 20) of patients, as evidenced by a negative postoperative prostate biopsy and no elevation on three successive prostate-specific antigen (PSA) determinations. Of the 20 patients, 13 (65%), 5 (25%), and 2 (10%) had PSA nadirs of less than 0.50 ng/mL, 0.50 to 1.00 ng/mL, and 1.01 to 2.00 ng/mL, respectively. Rectourethral fistula and urethral stricture were noted in 1 and 2 patients, respectively, and 1 patient underwent transurethral resection of the prostate because of prolonged urinary retention. CONCLUSIONS: Our results show that HIFU can be performed without an incision, with a less severe side effect profile, and, unlike most other prostate treatments, is repeatable. Transrectal HIFU may be a useful option for patients with localized prostate cancer. Its long-term efficacy will be determined by additional follow-up and a Phase II trial.
机译：目的：介绍我们的经直肠高强度聚焦超声（HIFU）治疗T1b-2N0M0期前列腺癌的初步临床结果。人们正在努力提供具有同等效力和较少副作用的微创替代治疗选择。 HIFU传递超声能量，使聚焦区域的组织快速热坏死，而不会损坏周围的组织。方法：我们使用改良的Sonablate-200 HIFU装置对20例经活检证实的局部前列腺癌患者进行了28例HIFU治疗。分析了所有患者特征和20例随访超过6个月（平均13.5）的临床结果。结果：100％（20名患者中的20名）患者获得了完全缓解，这由术后前列腺活检阴性和连续3次前列腺特异性抗原（PSA）测定无升高所证明。在这20名患者中，分别有13名（65％），5名（25％）和2名（10％）的PSA最低值分别低于0.50 ng / mL，0.50至1.00 ng / mL和1.01至2.00 ng / mL。 。分别有1例和2例患者出现了直肠外瘘和尿道狭窄，并且由于尿retention留时间延长，对1例患者进行了经尿道前列腺切除术。结论：我们的结果表明，HIFU可以在不进行切口的情况下进行，副作用较小，并且与大多数其他前列腺治疗不同，可重复使用。经直肠HIFU对于局限性前列腺癌患者可能是一个有用的选择。其长期疗效将通过进一步的随访和II期试验来确定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号